CTOs on the Move

Lasergen

www.lasergen.com

 
Lasergen is an emerging biotechnology company focused on commercializing novel technologies for DNA sequencing. Our expertise in nucleotide chemistry and next-generation sequencing has led to a number of key discoveries resulting in both game-changing sequencing chemistry (Lightning Terminators™) and a more accurate sequencing platform. While focusing on the development of current cutting-edge technology, our continued drive for innovation and extensive sequencing knowledge allows us to rapidly evolve and keep pace with fast-changing advances in the sequencing industry.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Lasergen raised $80M on 03/07/2016

Similar Companies

Cardiomend Inc

Cardiomend Inc is a Santa Barbara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurologica

Neurologica Corp. is a Danvers, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Megadyne Medical Products

Megadyne Medical Products is a Draper, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neuisys

Neuisys LLC is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cvrx

CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.